Ebixa
E494106
Ebixa is a brand-name medication containing memantine, used primarily to treat moderate to severe Alzheimer's disease.
All labels observed (1)
| Label | Occurrences |
|---|---|
| Ebixa canonical | 1 |
How this entity was disambiguated
This entity first appeared as the object of triple T5114928 — resolving that mention is where its identity was fixed. The disambiguator weighed these candidate entities and picked the highlighted one (or “None”, minting a new entity). This is how homonymy is resolved: the same surface form can point to different entities.
NED1
Entity disambiguation (via context triple)
gpt-5-mini-2025-08-07
Target entity: Ebixa Context triple: [Memantine, isMarketedUnderBrandName, Ebixa]
-
A.
Actian
Actian is a data management and analytics company known for its hybrid data platforms and database technologies used in enterprise applications.
-
B.
Jasper Technologies
Jasper Technologies is a cloud-based Internet of Things (IoT) platform provider known for enabling companies to manage and monetize connected devices and services.
-
C.
Nentego
Nentego is the autonym of the Nanticoke people, an Indigenous group historically located in the Mid-Atlantic region of what is now the United States.
-
D.
Looker
Looker is a modern business intelligence and data analytics platform that enables organizations to explore, visualize, and share insights from their data.
-
E.
Tableau
Tableau is a widely used data visualization and business intelligence software platform that enables users to analyze, explore, and present data through interactive dashboards and reports.
- F. None of above. chosen
- G. Unsure - the case is ambiguous/there is not enough information to decide.
NED2
Entity disambiguation (via description)
gpt-5-mini-2025-08-07
Target entity: Ebixa Target entity description: Ebixa is a brand-name medication containing memantine, used primarily to treat moderate to severe Alzheimer's disease.
-
A.
Actian
Actian is a data management and analytics company known for its hybrid data platforms and database technologies used in enterprise applications.
-
B.
Jasper Technologies
Jasper Technologies is a cloud-based Internet of Things (IoT) platform provider known for enabling companies to manage and monetize connected devices and services.
-
C.
Nentego
Nentego is the autonym of the Nanticoke people, an Indigenous group historically located in the Mid-Atlantic region of what is now the United States.
-
D.
Looker
Looker is a modern business intelligence and data analytics platform that enables organizations to explore, visualize, and share insights from their data.
-
E.
Tableau
Tableau is a widely used data visualization and business intelligence software platform that enables users to analyze, explore, and present data through interactive dashboards and reports.
- F. None of above. chosen
Statements (47)
| Predicate | Object |
|---|---|
| instanceOf |
brand-name medication
ⓘ
memantine-containing medicinal product ⓘ |
| actsOn | N-methyl-D-aspartate (NMDA) receptors ⓘ |
| administrationFrequency | once daily (maintenance dose) ⓘ |
| ATCCode | N06DX01 ⓘ |
| belongsTo | centrally acting anti-dementia drugs ⓘ |
| commonAdverseEffect |
confusion
ⓘ
constipation ⓘ dizziness ⓘ headache ⓘ hypertension ⓘ somnolence ⓘ |
| contraindication | hypersensitivity to memantine ⓘ |
| developedBy |
H. Lundbeck A/S
ⓘ
linked to:
Lundbeck
|
| dosageForm |
film-coated tablet
ⓘ
oral solution ⓘ |
| drugInteractionCaution |
amantadine
ⓘ
dextromethorphan ⓘ ketamine ⓘ other NMDA antagonists ⓘ |
| elimination | primarily renal excretion ⓘ |
| halfLife | about 60–80 hours ⓘ |
| hasActiveIngredient | memantine ⓘ |
| improves |
cognitive function in Alzheimer's disease
ⓘ
global functioning in Alzheimer's disease ⓘ |
| indication |
moderate Alzheimer's disease
ⓘ
severe Alzheimer's disease ⓘ |
| isBrandOf | memantine hydrochloride ⓘ |
| marketingAuthorizationHolder | Lundbeck ⓘ |
| marketingAuthorizationRegion | European Union ⓘ |
| maximumDailyDose | 20 mg memantine (typical in adults) ⓘ |
| maySlow | clinical deterioration in Alzheimer's disease ⓘ |
| metabolism | minimally metabolized in the liver ⓘ |
| notIndicatedFor | mild Alzheimer's disease ⓘ |
| pharmacologicalClass | NMDA receptor antagonist ⓘ |
| regulates | glutamatergic neurotransmission ⓘ |
| requires | prescription ⓘ |
| requiresCautionIn | severe renal impairment ⓘ |
| requiresDoseAdjustmentIn | renal impairment ⓘ |
| routeOfAdministration | oral ⓘ |
| targetPopulation |
adult patients
ⓘ
elderly patients ⓘ |
| therapeuticArea |
geriatrics
ⓘ
neurology ⓘ |
| titration | requires gradual dose escalation ⓘ |
| treats | Alzheimer's disease ⓘ |
| usedIn | symptomatic treatment of Alzheimer's disease ⓘ |
How these facts were elicited
The pipeline generated the facts above by prompting gpt-5.1 with this entity's name + description and the instruction below.
Instruction
You are a knowledge base construction expert. Given a subject entity and a description of it, return factual statements that you know for the subject as a JSON list of dictionaries(triples), where keys must be "subject", "predicate" and "object". The number of facts may be very high, between 25 to 50 or more, for very popular subjects. For less popular subjects, the number of facts can be very low, like 5 or 10. # Requirements - If you don't know the subject at all, return an empty list. - If the subject is not a named entity, return an empty list. - Include at least one triple where predicate is "instanceOf". - Do not get too wordy. - Separate several objects into multiple triples with one object.
Input
Subject: Ebixa Description of subject: Ebixa is a brand-name medication containing memantine, used primarily to treat moderate to severe Alzheimer's disease.
Referenced by (1)
Full triples — surface form annotated when it differs from this entity's canonical label.
subject linked to:
memantine